Case Study of the Week

A cystic mass of the pancreas was found in a 29 year old: is this a benign or cancerous cyst?
Read More

RedPath in the News

RedPath Integrated Pathology, Inc. Announces Professional Services Agreement with Allegheny General Hospital
Read

RedPath Launches Expanded Menu of Tests for Analysis of Pancreatic Cyst Fluids.
Read

More News

Events

More Events

Patients

Cancer is a molecular-based disease that is often impossible to diagnose through traditional microscopic testing.

Often, physicians are plagued with incomplete information that makes it difficult to achieve a definitive diagnosis.

In traditional testing, pathologists examine a biopsy under a microscope.  Often a definitive diagnosis is achieved. However when "indeterminate, atypical, suspicious, equivocal or non-diagnostic specimen" is the result, the patient is often required to return for additional biopsies and testing.  This could mean that several months pass before a patient receives a definitive diagnosis, delaying potentially lifesaving treatment and creating anxiety in the absence of the definitive diagnoses.

Further, with certain cancer types, physicians traditionally have had difficulty making a definitive diagnosis without major surgery.

  • 80% of pancreatic cancer is diagnosed late stage
  • Pseudomyxoma perotonei is one of many cytology case types for which the cellular sample is inadequate for traditional pathology methods
  • Up to 30% of breast cancer diagnoses are indeterminate
  • 30% of colon cancers are over/under staged with dramatic ramifications for the treatment plan

If you have reached the point where a definitive diagnosis has not been possible, your physician may choose to send your biopsy to RedPath for a molecular DNA-based test called PathFinderTG.  Only your physician can order PathFinderTG.  If he or she is not familiar with RedPath's tests, please refer them to this web site, www.redpathip.com.